MEDIPOST Co., Ltd. (KOSDAQ:078160)
South Korea · Delayed Price · Currency is KRW | Market Cap | 957.60B +153.7% |
| Revenue (ttm) | 73.59B +5.3% |
| Net Income | -97.90B |
| EPS | -2,925.08 |
| Shares Out | 39.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 596,195 |
| Average Volume | 533,719 |
| Open | 24,150 |
| Previous Close | 24,750 |
| Day's Range | 22,550 - 25,050 |
| 52-Week Range | 7,490 - 27,850 |
| Beta | 0.82 |
| RSI | 67.40 |
| Earnings Date | Jan 29, 2026 |
About MEDIPOST
MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co... [Read more]
Financial Performance
Financial StatementsNews
BDA Advises MEDIPOST on Growth Capital Raise
New York, NY December 18, 2025 --(PR.com)-- BDA Partners is pleased to announce that its client MEDIPOST, a leading stem cell therapeutics & cord blood banking biotech company in Korea, has raised g...